Saniona (SANION) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was SEK 4.7 million, down from SEK 9.8 million year-over-year, reflecting lower milestone and licensing income.

• Operating loss widened to SEK -56.5 million from SEK -16.5 million, driven by increased R&D and personnel costs as pipeline programs advanced.

• Net loss was SEK -46.2 million compared to a net profit of SEK 19.0 million in Q1 2025, with EPS at SEK -0.33 (basic and diluted).

• Cash and cash equivalents increased to SEK 532.0 million from SEK 260.7 million, supporting ongoing development and strategic flexibility.

• The company is advancing three proprietary CNS programs toward clinical trials and expects key milestones from partnered assets in the near term.

Financial highlights

• Revenue decreased to SEK 4.7 million from SEK 9.8 million year-over-year, mainly from licensing and partnership agreements.

• Operating expenses rose to SEK 61.2 million (from SEK 26.2 million), with R&D expenses at SEK 30.6 million (up from SEK 2.5 million).

• Net cash used in operating activities was SEK -50.1 million, compared to SEK -31.9 million in Q1 2025.

• Cash and cash equivalents at quarter-end were SEK 532.0 million, up from SEK 260.7 million.

• Equity ratio improved to 92% from 75% year-over-year.

Outlook and guidance

• Phase 1 studies for SAN2668 and SAN2465 are expected to begin in Q4 2026, with SAN2219 following in H1 2027.

• Near-term milestone payments anticipated from Jazz Pharmaceuticals (USD 7.5 million) and Acadia Pharmaceuticals (USD 10 million) upon clinical trial initiations.

• Continued focus on advancing internal pipeline, deepening strategic collaborations, and maintaining financial discipline.